Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

NCT02889523 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT02889523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02889523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 31, 2016
Completion date
September 30, 2029
Enrollment
214 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl, follicular lymphoma, lymphoma